Title : Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma.

Pub. Date : 2018 Jan 5

PMID : 29416795






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Whether temozolomide (TMZ)-induced mutagenesis of the TP53 DNA-binding domain (DBD) can drive the pathogenesis of gliosarcoma is unclear. Temozolomide tumor protein p53 Homo sapiens
2 Whether temozolomide (TMZ)-induced mutagenesis of the TP53 DNA-binding domain (DBD) can drive the pathogenesis of gliosarcoma is unclear. Temozolomide tumor protein p53 Homo sapiens
3 Ex vivo treatment of the GBM spheres with TMZ generated numerous variants in cancer driver genes, including TP53 and CDH1, which were mutated in the post-treatment tumor. Temozolomide tumor protein p53 Homo sapiens
4 Conclusions: TMZ-induced TP53 gain-of-function mutations can have a driving role in secondary gliosarcoma pathogenesis. Temozolomide tumor protein p53 Homo sapiens